Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions.

Tomas Koltai, Larry Fliegel
Author Information
  1. Tomas Koltai: Hospital del Centro Gallego de Buenos Aires, Buenos Aires, Argentina. ORCID
  2. Larry Fliegel: 12357University of Alberta, Edmonton, AB, Canada.

Abstract

The flavonoid silymarin extracted from the seeds of is a mixture of 6 flavolignan isomers. The 3 more important isomers are silybin (or silibinin), silydianin, and silychristin. Silybin is functionally the most active of these compounds. This group of flavonoids has been extensively studied and they have been used as hepato-protective substances for the mushroom intoxication and mainly chronic liver diseases such as alcoholic cirrhosis and nonalcoholic fatty liver. Hepatitis C progression is not, or slightly, modified by silymarin. Recently, it has also been proposed for SARS COVID-19 infection therapy. The biochemical and molecular mechanisms of action of these substances in cancer are subjects of ongoing research. Paradoxically, many of its identified actions such as antioxidant, promoter of ribosomal synthesis, and mitochondrial membrane stabilization, may seem protumoral at first sight, however, silymarin compounds have clear anticancer effects. Some of them are: decreasing migration through multiple targeting, decreasing hypoxia inducible factor-1α expression, inducing apoptosis in some malignant cells, and inhibiting promitotic signaling among others. Interestingly, the antitumoral activity of silymarin compounds is limited to malignant cells while the nonmalignant cells seem not to be affected. Furthermore, there is a long history of silymarin use in human diseases without toxicity after prolonged administration. The ample distribution and easy accessibility to milk thistle-the source of silymarin compounds, its over the counter availability, the fact that it is a weed, some controversial issues regarding bioavailability, and being a nutraceutical rather than a drug, has somehow led medical professionals to view its anticancer effects with skepticism. This is a fundamental reason why it never achieved bedside status in cancer treatment. However, in spite of all the antitumoral effects, silymarin actually has dual effects and in some cases such as pancreatic cancer it can promote stemness. This review deals with recent investigations to elucidate the molecular actions of this flavonoid in cancer, and to consider the possibility of repurposing it. Particular attention is dedicated to silymarin's dual role in cancer and to some controversies of its real effectiveness.

Keywords

References

  1. Pharmacol Toxicol. 2000 Jun;86(6):250-6 [PMID: 10895987]
  2. JAMA. 2012 Jul 18;308(3):274-82 [PMID: 22797645]
  3. Hepatol Res. 2003 Jul;26(3):217-224 [PMID: 12850694]
  4. Phytother Res. 2020 Dec;34(12):3359-3366 [PMID: 32762030]
  5. Fitoterapia. 2016 Mar;109:283-92 [PMID: 26851176]
  6. J Asian Nat Prod Res. 2007 Sep-Dec;9(6-8):593-602 [PMID: 17943553]
  7. PLoS One. 2016 Dec 28;11(12):e0168765 [PMID: 28030611]
  8. Integr Cancer Ther. 2007 Jun;6(2):120-9 [PMID: 17548791]
  9. Xenobiotica. 1994 Jan;24(1):17-24 [PMID: 8165818]
  10. Clin Mol Hepatol. 2015 Mar;21(1):49-59 [PMID: 25834802]
  11. Biochem Pharmacol. 2001 Jun 15;61(12):1487-95 [PMID: 11377378]
  12. Toxicology. 2006 Oct 29;227(3):211-6 [PMID: 16949716]
  13. Nat Rev Cancer. 2011 Aug 11;11(9):671-7 [PMID: 21833026]
  14. J Immunol. 1999 Dec 15;163(12):6800-9 [PMID: 10586080]
  15. Front Pharmacol. 2017 Aug 02;8:498 [PMID: 28824426]
  16. Methods Find Exp Clin Pharmacol. 1985 Aug;7(8):409-13 [PMID: 3001454]
  17. PLoS One. 2013 Dec 27;8(12):e83699 [PMID: 24386256]
  18. Toxicology. 2003 Aug 28;190(3):231-41 [PMID: 12927377]
  19. Mediterr J Hematol Infect Dis. 2016 Sep 01;8(1):e2016043 [PMID: 27648206]
  20. Inflammation. 2019 Feb;42(1):54-63 [PMID: 30178232]
  21. Hematol Oncol. 2010 Sep;28(3):124-32 [PMID: 19866452]
  22. Phytother Res. 2006 Dec;20(12):1036-9 [PMID: 17072885]
  23. Life Sci. 2019 Sep 1;232:116617 [PMID: 31260685]
  24. J Renal Inj Prev. 2012 Jan 01;1(1):3-5 [PMID: 25340091]
  25. Phytother Res. 2002 Mar;16 Suppl 1:S63-7 [PMID: 11933142]
  26. Int J Pharm. 2009 Jul 6;376(1-2):116-22 [PMID: 19409464]
  27. Hepatology. 2010 Jun;51(6):1912-21 [PMID: 20512985]
  28. Cancer Res. 2000 Apr 15;60(8):2290-9 [PMID: 10786697]
  29. Cancer Metastasis Rev. 2010 Sep;29(3):447-63 [PMID: 20714788]
  30. Endocrinology. 2005 Jan;146(1):175-85 [PMID: 15459112]
  31. Future Oncol. 2013 Aug;9(8):1231-7 [PMID: 23902251]
  32. Biochem Pharmacol. 1990 Jun 15;39(12):2027-34 [PMID: 2353942]
  33. Eur J Pharmacol. 2020 Jun 15;877:173066 [PMID: 32171791]
  34. Acta Trop. 2020 Nov;211:105613 [PMID: 32621935]
  35. Phytother Res. 2012 May;26(5):709-15 [PMID: 22016029]
  36. Biosci Biotechnol Biochem. 2013;77(5):1100-3 [PMID: 23649236]
  37. Antiviral Res. 2018 Oct;158:8-12 [PMID: 30076863]
  38. PLoS One. 2011;6(6):e21410 [PMID: 21731736]
  39. Exp Ther Med. 2016 Aug;12(2):1135-1140 [PMID: 27446333]
  40. Biomed Pharmacother. 2021 Jun;138:111459 [PMID: 33706132]
  41. Cancer Prev Res (Phila). 2013 May;6(5):455-65 [PMID: 23447564]
  42. Mol Carcinog. 1999 Dec;26(4):321-33 [PMID: 10569809]
  43. J Surg Res. 2016 Aug;204(2):398-409 [PMID: 27565076]
  44. Pharm Res. 2004 Jul;21(7):1263-73 [PMID: 15290869]
  45. Cold Spring Harb Perspect Biol. 2013 Dec 01;5(12):a016949 [PMID: 24296170]
  46. Pharmacol Res. 2006 Feb;53(2):104-12 [PMID: 16275123]
  47. Nat Prod Commun. 2013 Dec;8(12):1801-10 [PMID: 24555302]
  48. Phytother Res. 2021 Aug;35(8):4246-4257 [PMID: 33817867]
  49. PeerJ. 2020 Dec 16;8:e10373 [PMID: 33362957]
  50. Molecules. 2019 Apr 30;24(9): [PMID: 31052197]
  51. Methods Find Exp Clin Pharmacol. 1984 Oct;6(10):655-61 [PMID: 6513680]
  52. Altern Med Rev. 2005 Sep;10(3):193-203 [PMID: 16164374]
  53. Arzneimittelforschung. 1968 Jun;18(6):696-8 [PMID: 5755806]
  54. Biochem Biophys Res Commun. 2009 Dec 4;390(1):71-6 [PMID: 19778521]
  55. Biol Res. 1994;27(2):105-12 [PMID: 8640239]
  56. Carcinogenesis. 2007 Jul;28(7):1533-42 [PMID: 17389612]
  57. Prostate. 2001 Feb 1;46(2):98-107 [PMID: 11170137]
  58. Int Urol Nephrol. 2008;40(2):453-60 [PMID: 18368506]
  59. Anticancer Res. 1991 Mar-Apr;11(2):593-6 [PMID: 1905902]
  60. Int J Tissue React. 1988;10(3):177-81 [PMID: 3265704]
  61. World J Hepatol. 2014 Mar 27;6(3):144-9 [PMID: 24672644]
  62. Biol Pharm Bull. 1994 Mar;17(3):443-5 [PMID: 8019514]
  63. Cell Signal. 2013 Dec;25(12):2625-33 [PMID: 24012496]
  64. Anticancer Res. 2011 Nov;31(11):3767-73 [PMID: 22110198]
  65. Int J Cancer. 2007 May 1;120(9):2028-33 [PMID: 17230508]
  66. J Pharm Biomed Anal. 2007 Nov 30;45(4):635-41 [PMID: 17692492]
  67. Int Immunopharmacol. 2017 Sep;50:194-201 [PMID: 28672215]
  68. Bioorg Med Chem. 2006 Jun 1;14(11):3793-810 [PMID: 16466920]
  69. Apoptosis. 2011 Oct;16(10):1042-53 [PMID: 21779837]
  70. Am J Transl Res. 2016 Feb 15;8(2):1073-81 [PMID: 27158393]
  71. Int Immunopharmacol. 2015 Jan;24(1):1-6 [PMID: 25479723]
  72. J Cardiovasc Electrophysiol. 2003 Aug;14(8):861-7 [PMID: 12890050]
  73. J Basic Clin Physiol Pharmacol. 2019 Apr 24;30(4): [PMID: 31017870]
  74. Cell. 2011 Mar 4;144(5):646-74 [PMID: 21376230]
  75. Haematologica. 1993 Sep-Oct;78(5):340-1 [PMID: 8314167]
  76. Anticancer Res. 2000 Mar-Apr;20(2B):1311-6 [PMID: 10810441]
  77. Clin Cancer Res. 1998 Apr;4(4):1055-64 [PMID: 9563902]
  78. Neurosci Lett. 2016 Aug 26;629:256-261 [PMID: 27276653]
  79. Eur J Pharm Sci. 2016 Jun 30;89:163-71 [PMID: 27140843]
  80. Tumour Biol. 2016 Aug;37(8):11397-407 [PMID: 26984157]
  81. Arzneimittelforschung. 1975 Jan;25(1):89-96 [PMID: 125090]
  82. Int J Cancer. 1999 Feb 19;84(1):44-8 [PMID: 9988231]
  83. Cells. 2021 Jun 29;10(7): [PMID: 34209829]
  84. Org Biomol Chem. 2003 May 21;1(10):1684-9 [PMID: 12926355]
  85. Eur J Cancer. 1996 May;32A(5):877-82 [PMID: 9081370]
  86. Cancer Lett. 2008 Dec 8;272(1):61-9 [PMID: 18723275]
  87. Exp Clin Cardiol. 2007 Winter;12(4):179-87 [PMID: 18651002]
  88. Life Sci. 1988;43(12):975-81 [PMID: 3172970]
  89. Life Sci. 1986 Aug 25;39(8):717-26 [PMID: 3736343]
  90. World J Gastroenterol. 2020 Apr 14;26(14):1601-1612 [PMID: 32327909]
  91. Phytomedicine. 2010 Feb;17(2):116-25 [PMID: 19577454]
  92. Am J Gastroenterol. 1998 Feb;93(2):139-43 [PMID: 9468229]
  93. Chin J Integr Med. 2015 Dec;21(12):902-6 [PMID: 22528757]
  94. Toxicol Appl Pharmacol. 1979 Nov;51(2):265-75 [PMID: 531892]
  95. World J Urol. 2008 Aug;26(4):401-7 [PMID: 18408933]
  96. Oncotarget. 2017 Sep 8;8(54):92032-92042 [PMID: 29190895]
  97. Mol Med Rep. 2016 Apr;13(4):3243-8 [PMID: 26936429]
  98. J Control Release. 2021 Mar 10;331:515-524 [PMID: 33616078]
  99. Rocz Akad Med Bialymst. 2003;48:82-4 [PMID: 14737948]
  100. Oncogene. 2006 Feb 16;25(7):1053-69 [PMID: 16205633]
  101. J Clin Gastroenterol. 2003 Oct;37(4):336-9 [PMID: 14506392]
  102. Genes Cancer. 2013 Mar;4(3-4):97-104 [PMID: 24020000]
  103. J Hepatol. 1991 May;12(3):290-5 [PMID: 1940257]
  104. Cell Cycle. 2013 Nov 1;12(21):3390-404 [PMID: 24047698]
  105. Cell Microbiol. 2013 Nov;15(11):1866-82 [PMID: 23701235]
  106. Endocrinol Diabetes Nutr (Engl Ed). 2018 Apr;65(4):200-205 [PMID: 29422244]
  107. Med Welt. 1969 Apr 12;20(15):902-14 [PMID: 5784380]
  108. J Hepatol. 2001 Sep;35(3):392-8 [PMID: 11592601]
  109. Mutat Res. 2004 Nov 2;555(1-2):21-32 [PMID: 15476849]
  110. Discoveries (Craiova). 2016 Apr 1;4(1):e56 [PMID: 32309577]
  111. J Sci Food Agric. 2012 May;92(7):1441-7 [PMID: 22102319]
  112. Oncotarget. 2015 Aug 21;6(24):20604-20 [PMID: 26098771]
  113. Cancer Prev Res (Phila). 2016 Jan;9(1):89-95 [PMID: 26526990]
  114. J Neuroimmune Pharmacol. 2018 Mar;13(1):24-38 [PMID: 28808887]
  115. Antioxid Redox Signal. 2005 Jan-Feb;7(1-2):32-41 [PMID: 15650394]
  116. Eur J Neurosci. 2002 Dec;16(11):2103-12 [PMID: 12473078]
  117. Bioorg Med Chem Lett. 2000 Jan 17;10(2):157-60 [PMID: 10673101]
  118. Molecules. 2020 May 22;25(10): [PMID: 32455869]
  119. Carcinogenesis. 2013 Jul;34(7):1420-30 [PMID: 23585460]
  120. J Clin Pharmacol. 2010 Apr;50(4):434-49 [PMID: 19841158]
  121. Altern Med Rev. 2011 Sep;16(3):239-49 [PMID: 21951025]
  122. Inflammation. 2019 Aug;42(4):1203-1214 [PMID: 30806958]
  123. Am J Kidney Dis. 2012 Dec;60(6):896-903 [PMID: 22770926]
  124. Oncotarget. 2015 Dec 1;6(38):41146-61 [PMID: 26510913]
  125. Planta Med. 1986 Dec;(6):438-40 [PMID: 3562659]
  126. Crit Rev Oncog. 2015;20(1-2):49-64 [PMID: 25746104]
  127. Oncol Rep. 2010 Jun;23(6):1545-52 [PMID: 20428808]
  128. J Dermatol Sci. 2007 Apr;46(1):21-30 [PMID: 17289350]
  129. J Pharm Pharmacol. 1996 Sep;48(9):968-70 [PMID: 8910865]
  130. Toxicology. 2005 Nov 5;215(1-2):80-9 [PMID: 16076518]
  131. Cell Signal. 2021 Aug;84:110023 [PMID: 33901577]
  132. Eur J Drug Metab Pharmacokinet. 1993 Jul-Sep;18(3):289-97 [PMID: 8149949]
  133. Asian Pac J Cancer Prev. 2015;16(5):2087-92 [PMID: 25773855]
  134. Eur J Cancer. 2003 Nov;39(16):2403-10 [PMID: 14556934]
  135. Mol Carcinog. 2015 Mar;54(3):216-28 [PMID: 24127286]
  136. Hoppe Seylers Z Physiol Chem. 1977 Feb;358(2):141-7 [PMID: 844797]
  137. Phytomedicine. 2013 Dec 15;21(1):75-81 [PMID: 24012146]
  138. Phytomedicine. 2010 Dec 1;17(14):1090-4 [PMID: 20579862]
  139. Drugs. 2001;61(14):2035-63 [PMID: 11735632]
  140. FEBS Lett. 1998 Nov 27;440(1-2):8-12 [PMID: 9862414]
  141. Biochem Biophys Rep. 2018 Mar 31;14:20-25 [PMID: 29872730]
  142. Pharmacol Res. 2003 Jan;47(1):17-26 [PMID: 12526857]
  143. J Pharm Sci. 2003 Feb;92(2):250-7 [PMID: 12532374]
  144. Pharmacol Rep. 2020 Feb;72(1):199-207 [PMID: 32016841]
  145. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Feb;119(2):125-9 [PMID: 9669080]
  146. Phytother Res. 2010 Oct;24(10):1423-32 [PMID: 20564545]
  147. Neurochem Res. 2012 Sep;37(9):2053-63 [PMID: 22717697]
  148. Planta Med. 1998 Mar;64(2):138-42 [PMID: 9525106]
  149. Forsch Komplementmed. 2008 Feb;15(1):9-20 [PMID: 18334810]
  150. Invest New Drugs. 2007 Apr;25(2):139-46 [PMID: 17077998]
  151. Mol Carcinog. 2012 Oct;51(10):832-42 [PMID: 21882257]
  152. Eur J Cell Biol. 1997 Jul;73(3):189-97 [PMID: 9243179]
  153. PLoS One. 2017 Jan 31;12(1):e0170953 [PMID: 28141819]
  154. Arch Biochem Biophys. 2019 Aug 15;671:42-51 [PMID: 31085166]
  155. Life Sci. 1996;58(18):1591-600 [PMID: 8649189]
  156. Eur J Pharm Biopharm. 2006 Jul;63(3):288-94 [PMID: 16527467]
  157. PLoS One. 2013 Oct 15;8(10):e77366 [PMID: 24143225]
  158. Biochem Biophys Res Commun. 1997 Oct 9;239(1):334-9 [PMID: 9345320]
  159. Mol Carcinog. 2010 Oct;49(10):902-12 [PMID: 20721970]
  160. Chem Biol Interact. 2006 Jun 10;161(2):104-14 [PMID: 16643877]
  161. Am J Pathol. 1995 Aug;147(2):278-92 [PMID: 7543732]
  162. Biosci Biotechnol Biochem. 2010;74(11):2299-306 [PMID: 21071836]
  163. Biochem Pharmacol. 1977 Dec 15;26(24):2405-9 [PMID: 597328]
  164. J Pharm Biomed Anal. 2001 Aug;26(1):155-61 [PMID: 11451653]
  165. Prostate. 2010 Jun 1;70(8):848-55 [PMID: 20127732]
  166. Biochem Biophys Res Commun. 1998 Jun 18;247(2):294-301 [PMID: 9642119]
  167. Indian J Med Res. 2006 Nov;124(5):491-504 [PMID: 17213517]
  168. Antioxidants (Basel). 2019 Aug 14;8(8): [PMID: 31416138]
  169. Phytother Res. 2017 Mar;31(3):366-374 [PMID: 28124457]
  170. Experientia. 1979 Dec 15;35(12):1550-2 [PMID: 118049]
  171. Molecules. 2019 Mar 14;24(6): [PMID: 30875758]
  172. Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7490-5 [PMID: 10377442]
  173. Mol Cancer Ther. 2005 Feb;4(2):207-16 [PMID: 15713892]
  174. World J Gastroenterol. 2005 Apr 7;11(13):1896-902 [PMID: 15800977]
  175. Mol Carcinog. 2004 Jul;40(3):143-9 [PMID: 15224346]
  176. J Biol Chem. 2001 Jun 15;276(24):20809-12 [PMID: 11320076]
  177. Food Chem Toxicol. 2017 Aug;106(Pt A):424-429 [PMID: 28602599]
  178. Apoptosis. 2012 Aug;17(8):797-809 [PMID: 22555452]
  179. Med Princ Pract. 2014;23(2):140-4 [PMID: 24356575]
  180. Oncotarget. 2016 May 31;7(22):32006-14 [PMID: 26959886]
  181. Biomol Ther (Seoul). 2016 Jul 1;24(4):380-6 [PMID: 27068260]
  182. Arzneimittelforschung. 1968 Jun;18(6):688-96 [PMID: 5755805]
  183. Tumour Biol. 2018 May;40(5):1010428318776170 [PMID: 29764340]
  184. Mol Cancer Ther. 2011 Jan;10(1):104-16 [PMID: 21220495]
  185. Cell Signal. 2012 Dec;24(12):2291-6 [PMID: 22820499]
  186. Cancer Res. 2002 Jun 1;62(11):3063-9 [PMID: 12036915]
  187. J Agric Food Chem. 2013 May 1;61(17):4089-96 [PMID: 23570653]
  188. Biomed Pharmacother. 2018 Apr;100:191-197 [PMID: 29428667]
  189. Exp Ther Med. 2014 Jan;7(1):31-38 [PMID: 24348760]
  190. Med Sci Monit. 2002 Nov;8(11):BR439-43 [PMID: 12444368]
  191. Anticancer Res. 2008 Mar-Apr;28(2A):1119-27 [PMID: 18507063]
  192. Biomed Pharmacother. 2021 Oct;142:112024 [PMID: 34399200]
  193. J Pharmacol Sci. 2015 Jul;128(3):97-107 [PMID: 26117209]
  194. J Clin Transl Hepatol. 2020 Dec 28;8(4):454-458 [PMID: 33447529]
  195. Mol Carcinog. 2011 Oct;50(10):811-23 [PMID: 21574189]
  196. Iran J Basic Med Sci. 2021 Apr;24(4):514-523 [PMID: 34094034]
  197. J Hepatol. 1989 Jul;9(1):105-13 [PMID: 2671116]
  198. J Biosci. 2017 Mar;42(1):91-101 [PMID: 28229968]
  199. Drug Chem Toxicol. 2020 May;43(3):240-254 [PMID: 30033764]
  200. Clin Cancer Res. 2005 Jul 1;11(13):4962-7 [PMID: 16000596]
  201. Anticancer Res. 2012 Jul;32(7):2455-62 [PMID: 22753701]
  202. Planta Med. 1995 Apr;61(2):116-9 [PMID: 7753916]
  203. Cell Biochem Funct. 1997 Mar;15(1):27-33 [PMID: 9075334]
  204. Planta Med. 2002 Aug;68(8):676-9 [PMID: 12221586]
  205. Mol Cancer Ther. 2014 Jul;13(7):1860-72 [PMID: 24798868]
  206. J Turk Ger Gynecol Assoc. 2014 Mar 01;15(1):30-5 [PMID: 24790514]
  207. Cancer Lett. 2012 Dec 29;326(1):88-95 [PMID: 22863537]
  208. Cancer Treat Rev. 2017 Jul;58:61-69 [PMID: 28686955]
  209. J Viral Hepat. 2005 Nov;12(6):559-67 [PMID: 16255756]
  210. Naunyn Schmiedebergs Arch Pharmacol. 2021 Feb;394(2):337-348 [PMID: 32984915]
  211. Saudi Med J. 2009 Jan;30(1):98-103 [PMID: 19139781]
  212. Mol Pharmacol. 2001 May;59(5):1171-80 [PMID: 11306701]
  213. Cell Commun Signal. 2019 May 24;17(1):52 [PMID: 31126298]
  214. Arzneimittelforschung. 2003;53(6):420-7 [PMID: 12872613]
  215. Braz J Cardiovasc Surg. 2016 Nov-Dec;31(6):434-439 [PMID: 28076620]
  216. Biomed Pharmacother. 2018 May;101:49-57 [PMID: 29477472]
  217. J Orthop Surg Res. 2021 Feb 20;16(1):147 [PMID: 33610183]
  218. Oncol Lett. 2021 Jun;21(6):492 [PMID: 33968208]
  219. Bioorg Med Chem. 2004 Nov 1;12(21):5677-87 [PMID: 15465345]
  220. Clin Cancer Res. 2006 May 1;12(9):2944-50 [PMID: 16675592]
  221. Mem Inst Oswaldo Cruz. 1991;86 Suppl 2:79-85 [PMID: 1842018]
  222. Med Oncol. 2012 Dec;29(4):2512-8 [PMID: 22101790]
  223. Mol Cancer Ther. 2010 Dec;9(12):3233-43 [PMID: 21159609]
  224. Mol Carcinog. 2015 Nov;54(11):1328-39 [PMID: 25174976]
  225. Chem Biol Drug Des. 2011 Jun;77(6):494-9 [PMID: 21332948]
  226. Iran J Basic Med Sci. 2019 Sep;22(9):968-976 [PMID: 31807239]
  227. Oncol Rep. 2004 Feb;11(2):493-9 [PMID: 14719089]
  228. J Med Food. 2007 Sep;10(3):543-7 [PMID: 17887949]
  229. Carcinogenesis. 2001 Sep;22(9):1399-403 [PMID: 11532861]
  230. Cell Biol Int. 2008 Aug;32(8):888-92 [PMID: 18538589]
  231. J Surg Res. 2005 Sep;128(1):140-6 [PMID: 15993897]
  232. Avicenna J Phytomed. 2020 Mar-Apr;10(2):161-169 [PMID: 32257888]
  233. Cell Oncol (Dordr). 2017 Jun;40(3):235-246 [PMID: 28401485]
  234. PLoS One. 2013 Oct 16;8(10):e77731 [PMID: 24147068]
  235. Arzneimittelforschung. 1979;29(3):524-6 [PMID: 39576]
  236. Toxicol Lett. 2013 May 23;219(2):160-9 [PMID: 23500659]
  237. J Diabetes Res. 2016;2016:5147468 [PMID: 27340676]
  238. Gene. 2021 Feb 15;769:145239 [PMID: 33069805]
  239. Cancer Prev Res (Phila). 2009 Jan;2(1):74-83 [PMID: 19139021]
  240. Cancer Lett. 2013 Jul 28;335(2):251-8 [PMID: 23474498]
  241. J Natl Cancer Inst. 1997 Apr 16;89(8):556-66 [PMID: 9106644]
  242. J Cell Sci. 2012 Apr 15;125(Pt 8):2075-85 [PMID: 22637644]
  243. Clin Cancer Res. 2000 May;6(5):2104-19 [PMID: 10815938]
  244. Molecules. 2017 Jan 24;22(2): [PMID: 28125040]
  245. Biochem Pharmacol. 1995 Oct 12;50(8):1313-6 [PMID: 7488251]
  246. Food Chem Toxicol. 2018 Jun;116(Pt B):161-172 [PMID: 29660364]
  247. Oncol Lett. 2018 Jun;15(6):9868-9876 [PMID: 29805688]
  248. Cancer Biother Radiopharm. 2011 Jun;26(3):317-24 [PMID: 21711112]
  249. Int J Mol Sci. 2011;12(8):4861-71 [PMID: 21954330]
  250. Oncol Rep. 2012 Sep;28(3):999-1005 [PMID: 22736024]
  251. Cancer Res. 2005 May 15;65(10):4448-57 [PMID: 15899838]
  252. Anticancer Res. 2006 Nov-Dec;26(6B):4457-98 [PMID: 17201169]
  253. J Clin Invest. 1996 Jun 15;97(12):2792-802 [PMID: 8675690]
  254. Eur J Pharmacol. 2015 Oct 15;765:346-54 [PMID: 26342429]
  255. Int J Mol Sci. 2021 Apr 12;22(8): [PMID: 33921242]
  256. J Vet Pharmacol Ther. 2011 Apr;34(2):120-9 [PMID: 21395602]
  257. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2005 Jun;149(1):29-41 [PMID: 16170386]
  258. Mol Carcinog. 2013 Mar;52(3):195-206 [PMID: 22086675]
  259. BMC Dermatol. 2012 Oct 02;12:18 [PMID: 23031632]
  260. Oncotarget. 2017 Aug 7;8(40):68305-68316 [PMID: 28978118]
  261. J Med Food. 2013 Sep;16(9):778-84 [PMID: 23909904]
  262. Int J Cancer. 2002 Oct 10;101(5):461-8 [PMID: 12216075]
  263. Clin Cancer Res. 2002 Nov;8(11):3512-9 [PMID: 12429642]
  264. Circ Res. 2003 May 2;92(8):827-39 [PMID: 12730128]
  265. Biomed Res Int. 2015;2015:292797 [PMID: 25866771]
  266. J Enzyme Inhib Med Chem. 2013 Apr;28(2):412-7 [PMID: 22299585]
  267. J Pharmacol Sci. 2006 Dec;102(4):387-95 [PMID: 17170512]
  268. Dig Liver Dis. 2005 Nov;37(11):869-76 [PMID: 16169303]
  269. Int J Mol Sci. 2019 Jul 28;20(15): [PMID: 31357694]
  270. World J Gastroenterol. 2009 Apr 28;15(16):1943-50 [PMID: 19399925]
  271. J Vet Pharmacol Ther. 2007 Apr;30(2):132-8 [PMID: 17348898]
  272. Phytomedicine. 2020 Dec;79:153320 [PMID: 32920285]
  273. Acta Med Hung. 1989;46(4):289-95 [PMID: 2699920]
  274. Phytomedicine. 2009 Sep;16(9):839-44 [PMID: 19303749]
  275. Am J Med. 2002 Oct 15;113(6):506-15 [PMID: 12427501]
  276. Oncol Rep. 2019 Nov;42(5):1904-1914 [PMID: 31485597]
  277. Eur J Pharmacol. 2008 Sep 4;591(1-3):13-20 [PMID: 18599034]
  278. J Cosmet Dermatol. 2008 Mar;7(1):8-14 [PMID: 18254805]
  279. Asian Pac J Cancer Prev. 2016;17(5):2661-5 [PMID: 27268647]
  280. Cancer Res. 1999 Feb 1;59(3):622-32 [PMID: 9973210]
  281. J Hepatol. 2009 Jun;50(6):1102-11 [PMID: 19398228]
  282. Oncol Res. 2021 Sep 7;28(7):801-809 [PMID: 34030768]
  283. Phytomedicine. 2010 Oct;17(12):963-73 [PMID: 20833521]
  284. Oncol Rep. 2015 Jun;33(6):2711-8 [PMID: 25891311]
  285. Gastroenterology. 2007 May;132(5):1925-36 [PMID: 17484885]
  286. Eur J Drug Metab Pharmacokinet. 1992 Jan-Mar;17(1):39-44 [PMID: 1499596]
  287. Life Sci. 2019 Jan 15;217:70-80 [PMID: 30452972]
  288. J Med Food. 2015 Mar;18(3):290-8 [PMID: 25133972]
  289. Prostate. 2002 Nov 1;53(3):211-7 [PMID: 12386921]
  290. Invest New Drugs. 2009 Jun;27(3):233-40 [PMID: 18665326]
  291. Biochem Biophys Res Commun. 2000 Sep 16;276(1):371-8 [PMID: 11006131]
  292. Tumour Biol. 2012 Oct;33(5):1739-44 [PMID: 22678979]
  293. Expert Opin Ther Targets. 2011 Jul;15(7):817-28 [PMID: 21391891]
  294. Experientia. 1979 Dec 15;35(12):1548-60 [PMID: 118048]
  295. Cancer Lett. 2013 Jun 28;334(1):109-17 [PMID: 23022268]
  296. J Pharmacol Exp Ther. 2014 May;349(2):268-78 [PMID: 24472723]
  297. Int J Oncol. 2017 Oct;51(4):1219-1226 [PMID: 28791405]
  298. Carcinogenesis. 1999 Nov;20(11):2101-8 [PMID: 10545412]
  299. J Hepatol. 2020 Jan;72(1):125-134 [PMID: 31562907]
  300. Parasit Vectors. 2012 Jan 11;5:9 [PMID: 22236605]
  301. J Surg Res. 2003 Jul;113(1):133-8 [PMID: 12943822]
  302. Nat Prod Rep. 2014 Sep;31(9):1138-57 [PMID: 24977260]
  303. Anticancer Drugs. 2015 Jun;26(5):475-86 [PMID: 25603021]
  304. Cell Cycle. 2016 Dec 16;15(24):3413-3418 [PMID: 27753543]
  305. Arch Biochem Biophys. 2020 Sep 15;690:108479 [PMID: 32679194]
  306. J Mol Recognit. 2021 Jul;34(7):e2888 [PMID: 33624887]
  307. Int J Clin Pharmacol Ther Toxicol. 1992 Apr;30(4):134-8 [PMID: 1572758]
  308. PLoS One. 2011;6(7):e23000 [PMID: 21829575]
  309. Eur J Med Chem. 2017 Jun 16;133:365-378 [PMID: 28411546]
  310. Molecules. 2019 Jun 07;24(11): [PMID: 31181687]
  311. Acta Med Iran. 2013;51(9):591-8 [PMID: 24338188]
  312. Carcinogenesis. 1994 Jun;15(6):1099-103 [PMID: 8020140]
  313. Epigenetics. 2012 Oct;7(10):1161-72 [PMID: 22965008]
  314. Gastroenterol Clin Biol. 1989;13(2):120-4 [PMID: 2707520]
  315. Int J Clin Pharmacol Ther. 1994 Nov;32(11):614-7 [PMID: 7874377]
  316. Eur J Pharmacol. 2014 Nov 15;743:79-88 [PMID: 25242120]
  317. Integr Cancer Ther. 2007 Jun;6(2):110-9 [PMID: 17548790]
  318. Jpn J Cancer Res. 2002 Jan;93(1):42-9 [PMID: 11802807]
  319. Med Res Rev. 2021 Jul;41(4):2195-2246 [PMID: 33587317]
  320. CNS Neurosci Ther. 2013 Nov;19(11):847-53 [PMID: 24118806]
  321. Nephrol Dial Transplant. 1996 Jan;11(1):55-62 [PMID: 8649653]
  322. Mol Cell Biochem. 2008 Jun;313(1-2):53-61 [PMID: 18373278]
  323. Eur J Pharmacol. 2018 Aug 5;832:39-49 [PMID: 29782854]
  324. Biomed Environ Sci. 2015 Jan;28(1):36-43 [PMID: 25566861]
  325. J Urol. 2004 May;171(5):1934-8 [PMID: 15076315]
  326. Cancer Med. 2014 Apr;3(2):215-24 [PMID: 24574320]
  327. Anticancer Drugs. 2015 Jun;26(5):487-97 [PMID: 25603020]
  328. Eur Urol. 2005 Dec;48(6):922-30; discussion 930-1 [PMID: 16263208]
  329. Am J Transl Res. 2009 Jan 01;1(1):80-6 [PMID: 19966941]
  330. Pharm Res. 2009 Dec;26(12):2558-67 [PMID: 19779968]
  331. Biochem Biophys Res Commun. 1999 Sep 24;263(2):528-36 [PMID: 10491326]
  332. Int J Cancer. 2008 May 1;122(9):2050-6 [PMID: 18172859]
  333. Med Oncol. 2020 Feb 15;37(3):18 [PMID: 32062757]
  334. Biochem Pharmacol. 1986 Feb 1;35(3):538-41 [PMID: 3004503]
  335. Clin Exp Metastasis. 2003;20(3):195-201 [PMID: 12741678]
  336. Anticancer Res. 2003 May-Jun;23(3B):2649-55 [PMID: 12894553]
  337. J Steroid Biochem Mol Biol. 2003 Aug;86(2):179-88 [PMID: 14568570]
  338. Expert Rev Anticancer Ther. 2006 Nov;6(11):1559-68 [PMID: 17134361]
  339. Yakugaku Zasshi. 1975 Aug;95(8):1017-21 [PMID: 1237601]
  340. Comb Chem High Throughput Screen. 2021;24(6):879-890 [PMID: 32819226]
  341. Br J Cancer. 1996 Dec;74(12):2036-41 [PMID: 8980410]
  342. Free Radic Biol Med. 2017 Sep;110:240-249 [PMID: 28625483]
  343. Hepatology. 2013 Mar;57(3):1262-71 [PMID: 23213025]
  344. Clin Cancer Res. 2008 Dec 1;14(23):7773-80 [PMID: 19047104]
  345. Ren Fail. 1998 May;20(3):471-9 [PMID: 9606735]
  346. Anticancer Res. 2014 Apr;34(4):1723-9 [PMID: 24692702]
  347. Nat Med. 2005 Sep;11(9):992-7 [PMID: 16127434]
  348. Daru. 2014 Jan 24;22(1):24 [PMID: 24460990]
  349. Cases J. 2009 Aug 07;2:6251 [PMID: 19918565]
  350. J Oncol Pharm Pract. 2022 Jun;28(4):827-835 [PMID: 33861657]
  351. Arzneimittelforschung. 1973 Sep;23(9):1322-6 [PMID: 4801229]
  352. Free Radic Biol Med. 1999 Jan;26(1-2):174-83 [PMID: 9890652]
  353. Cancer Res. 1998 May 1;58(9):1920-9 [PMID: 9581834]
  354. Mol Ther Oncolytics. 2019 May 17;14:130-138 [PMID: 31194121]
  355. Mol Cancer Ther. 2002 May;1(7):525-32 [PMID: 12479270]
  356. Food Chem Toxicol. 2013 Oct;60:360-8 [PMID: 23916468]
  357. Cancer Res. 2000 Oct 15;60(20):5617-20 [PMID: 11059749]
  358. Anticancer Drugs. 2020 Sep;31(8):785-791 [PMID: 32209841]
  359. Cancer Res. 1994 Aug 1;54(15):3988-92 [PMID: 7518347]
  360. Mol Cancer. 2013 Jan 17;12:4 [PMID: 23327284]
  361. Urolithiasis. 2020 Apr;48(2):109-116 [PMID: 31506763]
  362. Sci Rep. 2015 Jun 16;5:11421 [PMID: 26078201]
  363. Mol Cancer Ther. 2006 Jul;5(7):1660-8 [PMID: 16891451]
  364. Carcinogenesis. 2006 Sep;27(9):1739-47 [PMID: 16597642]
  365. Int J Cancer. 2008 Jul 1;123(1):41-50 [PMID: 18435416]
  366. Hepatology. 2000 Aug;32(2):442-4 [PMID: 10960282]
  367. Oncol Lett. 2017 Dec;14(6):8035-8041 [PMID: 29344246]
  368. Mol Carcinog. 2001 Apr;30(4):224-36 [PMID: 11346885]
  369. Antivir Ther. 2013;18(2):141-7 [PMID: 23011959]
  370. Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):933-9 [PMID: 14504208]
  371. Clin Cancer Res. 2012 Oct 15;18(20):5546-53 [PMID: 23071356]
  372. J Pharmacol Exp Ther. 2003 Mar;304(3):1258-67 [PMID: 12604704]
  373. Physiol Res. 1998;47(1):1-7 [PMID: 9708694]
  374. Forsch Komplementmed. 2013;20(4):261-6 [PMID: 24030447]
  375. Br J Clin Pharmacol. 1987 Dec;24(6):747-52 [PMID: 2449903]
  376. Clin Cancer Res. 2005 Dec 1;11(23):8441-8 [PMID: 16322307]
  377. Anticancer Res. 1994 May-Jun;14(3A):1113-6 [PMID: 8074460]
  378. Phytomedicine. 2009 Jun;16(6-7):573-80 [PMID: 19181503]
  379. Adv Exp Med Biol. 2016;929:25-44 [PMID: 27771919]
  380. Acta Pharmacol Sin. 2009 Aug;30(8):1162-8 [PMID: 19578386]
  381. Carcinogenesis. 2007 May;28(5):977-87 [PMID: 17116726]
  382. Mol Carcinog. 2015 Sep;54(9):730-41 [PMID: 24615813]
  383. Cancer Res. 2011 Dec 1;71(23):7301-11 [PMID: 21978933]
  384. Mol Carcinog. 2010 Mar;49(3):247-58 [PMID: 19908243]
  385. Cancer Res. 2007 Sep 1;67(17):8274-84 [PMID: 17804742]
  386. Molecules. 2021 Mar 25;26(7): [PMID: 33805938]
  387. Arzneimittelforschung. 1992 Jul;42(7):964-8 [PMID: 1329780]
  388. Biomed Pharmacother. 2015 Aug;74:257-64 [PMID: 26349994]
  389. Am Fam Physician. 2005 Oct 1;72(7):1285-8 [PMID: 16225032]
  390. J Mol Recognit. 2020 Jan;33(1):e2812 [PMID: 31531903]
  391. Pharm Biol. 2017 Dec;55(1):729-739 [PMID: 28027688]
  392. Leuk Lymphoma. 2016 May;57(5):1154-62 [PMID: 26133723]
  393. Am J Cancer Res. 2016 Jun 01;6(6):1287-301 [PMID: 27429844]
  394. Cancer Res. 2010 Mar 15;70(6):2368-78 [PMID: 20215518]
  395. Cell Prolif. 2009 Apr;42(2):229-40 [PMID: 19317806]

MeSH Term

COVID-19
Humans
Silybum marianum
Neoplasms
SARS-CoV-2
Silybin
Silymarin

Chemicals

Silymarin
Silybin

Word Cloud

Created with Highcharts 10.0.0silymarincancercompoundseffectscellsflavonoidisomerssilybinsubstancesliverdiseasesmolecularactionsantioxidantseemanticancerdecreasingmigrationmalignantantitumoralmilkdualextractedseedsmixture6flavolignan3importantsilibininsilydianinsilychristinSilybinfunctionallyactivegroupflavonoidsextensivelystudiedusedhepato-protectivemushroomintoxicationmainlychronicalcoholiccirrhosisnonalcoholicfattyHepatitisCprogressionslightlymodifiedRecentlyalsoproposedSARSCOVID-19infectiontherapybiochemicalmechanismsactionsubjectsongoingresearchParadoxicallymanyidentifiedpromoterribosomalsynthesismitochondrialmembranestabilizationmayprotumoralfirstsighthoweverclearare:multipletargetinghypoxiainduciblefactor-1αexpressioninducingapoptosisinhibitingpromitoticsignalingamongothersInterestinglyactivitylimitednonmalignantaffectedFurthermorelonghistoryusehumanwithouttoxicityprolongedadministrationampledistributioneasyaccessibilitythistle-thesourcecounteravailabilityfactweedcontroversialissuesregardingbioavailabilitynutraceuticalratherdrugsomehowledmedicalprofessionalsviewskepticismfundamentalreasonneverachievedbedsidestatustreatmentHoweverspiteactuallycasespancreaticcanpromotestemnessreviewdealsrecentinvestigationselucidateconsiderpossibilityrepurposingParticularattentiondedicatedsilymarin'srolecontroversiesrealeffectivenessRoleSilymarinCancerTreatment:FactsHypothesesQuestionsinvasionthistle

Similar Articles

Cited By